Elsevier

Clinical Therapeutics

Volume 31, Issue 10, October 2009, Pages 2152-2169
Clinical Therapeutics

Modeling the impact of a new vaccine on pneumococcal and nontypable Haemophilus influenzae diseases: A new simulation model

https://doi.org/10.1016/j.clinthera.2009.10.014Get rights and content

Abstract

Background: A heptavalent pneumococcal conjugate vaccine (PCV-7) is available to immunize infants against pneumococcal disease. However, a recently developed vaccine, pneumococcal nontypable Haemophilus influenzae protein D-conjugate vaccine (PHiD-CV), has recently been licensed. PHiD-CV contains 3 additional Streptococcus pneumoniae serotypes and may provide protection against nontypable H influenzae (NTHi) infection. New health economic models are required to model the impact of PHiD-CV and compare its effectiveness with PCV-7.

Objectives: The aim of this article was to design a model capable of projecting the pneumococcal and NTHi disease burden on the entire UK population under different schedules of PCV-7 and PHiD-CV. This model should also be capable of modeling the net indirect effect of vaccination (ie, the sum of serotype replacement and herd protection).

Methods: A static, deterministic, age-compartmental model was created based on published information and the input of a board of experts in pneumococcal disease. The model presents results from both a payerbased and societal perspective. A 1-way sensitivity analysis was used to demonstrate the robustness of the model. Key parameters included the case fatality ratio for bacteremia, the hospitalization rate for acute otitis media (AOM), and parameters surrounding the extent of the net indirect effect of vaccination.

Results: Excluding net indirect effect, 325 cases of invasive pneumococcal disease (IPD), 619 hospitalizations for pneumonia, and 9016 general practitioner visits for AOM would be prevented annually with the current PCV-7 2 + 1 program. These numbers would increase to 374, 755, and 30,920, respectively, using a PHiD-CV 2 + 1 regimen, or to 503, 994, and 47,180 using a PHiD-CV 3 + 1 regimen. When a net indirect effect of 38% is considered, health benefits could be much larger; 2417, 2451, and 3045 IPD cases would be prevented in the 3 scenarios, respectively.

Conclusions: It is predicted that any vaccination program in the United Kingdom would have a striking impact on the incidence of all outcomes analyzed. A PHiD-CV 3 + 1 schedule is predicted to have a greater effect than PCV-7 in all scenarios. While the primary purpose of vaccination would be to prevent IPD and pneumonia hospitalizations, an additional benefit would be a noticeable reduction in AOM incidence. While the predictions made by the model were based on informed reasoning, all of its projected estimations remain approximations that are dependent on the inputs used to configure it, a limitation that is common to all simulation models.

References (53)

  • AP Johnson et al.

    Morbidity and mortality of pneumococcal meningitis and serotypes of causative strains prior to introduction of the 7-valent conjugant pneumococcal vaccine in England

    J Infect.

    (2007)
  • A Melegaro et al.

    Costeffectiveness analysis of pneumococcal conjugate vaccination in England and Wales

    Vaccine.

    (2004)
  • S Black et al.

    Assessing costs and cost effectiveness of pneumococcal disease and vaccination within Kaiser Permanente

    Vaccine.

    (2000)
  • CG Grijalva et al.

    Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: A time-series analysis

    Lancet

    (2007)
  • JC Nelson et al.

    Impact of the introduction of pneu-mococcal conjugate vaccine on rates of community acquired pneumonia in children and adults

    Vaccine.

    (2008)
  • D Tarragó et al.

    Identification of pneumococcal serotypes from culture-negative clinical specimens by novel real-time PCR

    Clin Microbiol Infect.

    (2008)
  • CG Whitney et al.

    Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine

    N Engl J Med.

    (2003)
  • S Black et al.

    Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children

    Pediatr Infect Dis J.

    (2000)
  • MB Rennels et al.

    Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM197 in United States infants

    Pediatrics.

    (1998)
  • Pneumococcal. Immunisation Against Infectious Disease—“The Green Book.”

  • WP Hausdorff

    Invasive pneumococcal disease in children: Geographic and temporal variations in incidence and serotype distribution

    Eur J Pediatr.

    (2002)
  • Phase 3 data indicate investigational 13-valent vaccine may broaden protection against pneumococcal disease in children younger than two (press release)

    (2008)
  • Synflorix

    GlaxoSmithKline's pneumococcal vaccine, receives European authorisation (press release)

    (2009)
  • GT Ray et al.

    Cost-effectiveness of pneumococcal conjugate vaccine: Evidence from the first 5 years of use in the United States incorporating herd effects

    Pediatr Infect Dis J.

    (2006)
  • P De Wals et al.

    Pneumococcal immunization program: Cost-utility analysis for Quebec

    CanJ Infect Dis.

    (1999)
  • B Chevallier et al.

    Safety and reactogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with routine childhood vaccines

    Pediatr Infect Dis J.

    (2009)
  • Cited by (41)

    • Dynamic transmission models and economic evaluations of pneumococcal conjugate vaccines: a quality appraisal and limitations

      2020, Clinical Microbiology and Infection
      Citation Excerpt :

      Transmission models can be deterministic, which yield the expected number of cohorts of people according to their infectious state (S, E, I, R) and the parameters, or individual-based, which are simulations that possess an inherent randomness and stochasticity that is governed by behavioural rules. While several static transmission models have been developed [15–19], these do not account for the change in indirect effects over time, and therefore are not able to capture the post-vaccination dynamics as effectively as dynamic transmission models (DTMs). As DTMs aid us in estimating the indirect effects and disease reduction caused by vaccination, they can be extended to evaluate the economic benefit of choosing one vaccine over another.

    View all citing articles on Scopus
    View full text